Home › Companies › BioMarin Pharmaceutical Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BioMarin Pharmaceutical Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 2, 2026: 13 items on BioMarin Pharmaceutical Inc.’s Form 8-K, filed June 4, 2026: 10 elected · 3 approved.
Notable dissent: 1 director (11.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BioMarin Pharmaceutical Inc. in the interactive database Compare manager voting policies
These tallies are BioMarin Pharmaceutical Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth M. Anderson | 152,826,855 | 11,325,400 | 41,995 | -- | 11,619,042 | 93% | Elected | — |
| Elect Director: Barbara W. Bodem | 162,832,241 | 796,989 | 565,020 | -- | 11,619,042 | 99.5% | Elected | — |
| Elect Director: Ian T. Clark | 144,380,101 | 19,160,530 | 653,619 | -- | 11,619,042 | 88% | Elected | — |
| Elect Director: Athena Countouriotis | 162,326,065 | 1,823,399 | 44,786 | -- | 11,619,042 | 99% | Elected | — |
| Elect Director: Willard Dere | 161,112,606 | 2,973,541 | 108,103 | -- | 11,619,042 | 98% | Elected | — |
| Elect Director: Mark J. Enyedy | 161,113,325 | 3,032,040 | 48,885 | -- | 11,619,042 | 98% | Elected | — |
| Elect Director: Alexander Hardy | 163,115,633 | 1,028,506 | 50,111 | -- | 11,619,042 | 99.4% | Elected | — |
| Elect Director: Maykin Ho | 160,849,437 | 3,300,117 | 44,696 | -- | 11,619,042 | 98% | Elected | — |
| Elect Director: Robert J. Hombach | 160,262,501 | 3,342,524 | 589,225 | -- | 11,619,042 | 98% | Elected | — |
| Elect Director: Timothy P. Walbert | 158,544,683 | 5,554,116 | 95,451 | -- | 11,619,042 | 97% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy | 170,867,335 | 4,850,526 | 95,431 | -- | -- | 97% | Approved | — |
| 3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement | 142,742,800 | 21,287,767 | 163,683 | -- | 11,619,042 | 87% | Approved | — |
| 4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment | 158,561,867 | 5,480,380 | 152,003 | -- | 11,619,042 | 97% | Approved | — |
Source: BioMarin Pharmaceutical Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
510 asset managers disclosed a vote on at least one BioMarin Pharmaceutical Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Prior year: 99.4% for (May 20, 2025 meeting) unchanged
Description as filed by funds: Election of Directors: Alexander Hardy
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Alexander Hardy”): 163,115,633 for, 1,028,506 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 80,242,958 for, 4,676 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,783 | 3 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.0% for (May 20, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: Election of Directors: Athena Countouriotis
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Athena Countouriotis”): 162,326,065 for, 1,823,399 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 80,242,956 for, 4,678 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,781 | 5 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Prior year: 99.4% for (May 20, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: Election of Directors: Barbara W. Bodem
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 162,832,241 for, 796,989 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 80,242,957 for, 4,674 against, 30,101 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,782 | 1 | 1 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Prior year: 96.8% for (May 20, 2025 meeting) ▼ 3.7 pts
Description as filed by funds: Election of Directors: Elizabeth M. Anderson
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 152,826,855 for, 11,325,400 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 77,587,955 for, 2,659,678 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,815 | 20,971 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,284,559 | 0 | 0 | Against |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 0 | 594,303 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 415,047 | 32,118 | 0 | 0 | Mixed |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 91,582 | 150,338 | 0 | 0 | Mixed |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Ian T. Clark
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Ian T. Clark”): 144,380,101 for, 19,160,530 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 77,983,205 for, 2,264,427 against, 30,101 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 27,413,765 | 749,019 | 1 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,367,572 | 20,391 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,645 | 4,524 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 69,448 | 207,762 | 0 | 0 | Mixed |
| Russell Investments | 0 | 249,772 | 0 | 0 | Against |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 0 | 230,791 | 0 | 0 | Against |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 182,655 | 10,836 | 0 | 0 | Mixed |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 99.2% for (May 20, 2025 meeting) ▼ 1.0 pts
Description as filed by funds: Election of Directors: Mark J. Enyedy
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 161,113,325 for, 3,032,040 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 79,485,343 for, 762,290 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,151,152 | 11,634 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 0 | 594,303 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.9% for (May 20, 2025 meeting) ▼ 0.9 pts
Description as filed by funds: Election of Directors: Maykin Ho
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Maykin Ho”): 160,849,437 for, 3,300,117 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 79,854,217 for, 393,416 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,835 | 20,951 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.4% for (May 20, 2025 meeting) ▼ 0.4 pts
Description as filed by funds: Election of Directors: Robert J. Hombach
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Robert J. Hombach”): 160,262,501 for, 3,342,524 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 79,854,217 for, 393,414 against, 30,101 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,835 | 20,949 | 1 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Prior year: 99.6% for (May 20, 2025 meeting) ▼ 3.0 pts
Description as filed by funds: Election of Directors: Timothy P. Walbert
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 158,544,683 for, 5,554,116 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 78,377,400 for, 1,870,232 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,770 | 14 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,284,559 | 0 | 0 | Against |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 415,047 | 32,118 | 0 | 0 | Mixed |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 91,582 | 150,338 | 0 | 0 | Mixed |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.5% for (May 20, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: Election of Directors: Willard Dere
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Willard Dere”): 161,112,606 for, 2,973,541 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 79,854,218 for, 393,415 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,836 | 20,950 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 95.3% for (May 20, 2025 meeting) ▲ 1.3 pts
Description as filed by funds: To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.
BioMarin Pharmaceutical Inc.’s own tally for this item (“4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes”): 158,561,867 for, 5,480,380 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved the Plan Amendment.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 133 asset managers below reported 79,958,867 for, 184,700 against, 30,100 abstained, 2,907 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,774 | 11 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,084 | 85 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. All 133 are in the interactive database (link above).
Combines 12 wordings of this item as funds reported it.
87% Approved · of votes cast
Prior year: 93.8% for (May 20, 2025 meeting) ▼ 6.8 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.
BioMarin Pharmaceutical Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 142,742,800 for, 21,287,767 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 27,413,761 | 749,025 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,194,877 | 193,086 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,645 | 4,524 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,203 | 449 | 0 | 0 | For |
| Dimensional | 0 | 1,284,559 | 0 | 0 | Against |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 0 | 594,303 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 327,125 | 120,040 | 0 | 0 | Mixed |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 0 | 327,820 | 0 | 0 | Against |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 249,772 | 0 | 0 | Against |
| John Hancock | 91,582 | 150,338 | 0 | 0 | Mixed |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 13,369 | 207,900 | 0 | 0 | Mixed |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 93,135 | 100,356 | 0 | 0 | Mixed |
Fund voting reports, all 123 managers: 75,111,556 for, 5,126,000 against, 34,773 abstained, 187 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 13,864,195 | 0 | 0 | 0 | For |
| Dodge & Cox | 13,772,459 | 0 | 0 | 0 | For |
| State Street | 6,918,932 | 52,659 | 0 | 0 | For |
| BlackRock | 6,952,894 | 17,633 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,945,799 | 0 | 0 | 0 | For |
| Fidelity | 3,800,287 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,788,854 | 0 | 0 | 0 | For |
| AQR | 3,583,705 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 3,496,878 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 2,620,148 | 0 | 0 | 0 | For |
| Invesco | 2,095,593 | 0 | 0 | 0 | For |
| Charles Schwab | 1,671,989 | 449 | 0 | 0 | For |
| Citadel | 1,604,159 | 0 | 0 | 0 | For |
| Vanguard | 1,518,540 | 0 | 0 | 0 | For |
| Northern Trust | 1,368,466 | 17,542 | 0 | 0 | For |
| DnB Asset Management AS | 1,236,011 | 0 | 0 | 0 | For |
| Janus Henderson | 1,198,102 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,180,617 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,180,133 | 0 | 0 | 0 | For |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 0 | 864,198 | 0 | 0 | Against |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 851,556 | 0 | 0 | 0 | For |
| Dimensional | 0 | 826,266 | 0 | 0 | Against |
| Wellington | 0 | 803,958 | 0 | 0 | Against |
| Swedbank Robur Fonder AB | 0 | 752,187 | 0 | 0 | Against |
| River Road Asset Management, LLC | 0 | 740,265 | 0 | 0 | Against |
Institutional-manager reports, all 416 managers: 94,170,897 for, 14,625,404 against, 14,774 abstained, 2,600 not voted, 52 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 95.8% for (May 20, 2025 meeting) ▲ 1.5 pts
Description as filed by funds: To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.
BioMarin Pharmaceutical Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 170,867,335 for, 4,850,526 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2026.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 123 asset managers below reported 80,224,219 for, 19,014 against, 30,100 abstained, 187 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,151,147 | 11,639 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,025 | 144 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 212,180 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of May 20, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 193,268,870 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 14.57% |
| 2 | BlackRock | 6.05% |
| 3 | Dodge & Cox | 5.94% |
| 4 | Fidelity | 3.31% |
| 5 | Capital Group | 1.74% |
| 6 | State Street | 1.53% |
| 7 | PRIMECAP Odyssey Funds | 1.21% |
| 8 | First Trust | 0.82% |
| 9 | Charles Schwab | 0.81% |
| 10 | Dimensional | 0.66% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP MANAGEMENT CO/CA/ | 7.17% |
| 2 | Dodge & Cox | 7.13% |
| 3 | State Street | 3.61% |
| 4 | BlackRock | 3.61% |
| 5 | VIKING GLOBAL INVESTORS LP | 3.59% |
| 6 | Fidelity | 1.97% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.96% |
| 8 | AQR | 1.85% |
| 9 | Capital Research Global Investors | 1.81% |
| 10 | Vestal Point Capital, LP | 1.36% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| The Vanguard Group | 18,992,533 | 9.83% | Proxy statement (DEF 14A), table as of April 7, 2026 |
| BlackRock, Inc. | 17,560,751 | 9.09% | Schedule 13G, filed January 21, 2026 |
| PRIMECAP Management Company | 15,795,383 | 8.17% | Proxy statement (DEF 14A), table as of April 7, 2026 |
| Dodge & Cox | 13,994,063 | 7.24% | Proxy statement (DEF 14A), table as of April 7, 2026 |
| State Street | 7,295,079 | 3.77% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 4,697,834 | 2.43% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 3,819,441 | 1.98% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 3,802,930 | 1.97% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 3,567,031 | 1.85% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 2,315,620 | 1.20% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 193,268,870 shares outstanding, as reported by BioMarin Pharmaceutical Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BioMarin Pharmaceutical Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 510 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 7,512 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BioMarin Pharmaceutical Inc.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BioMarin Pharmaceutical Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioMarin Pharmaceutical Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BioMarin Pharmaceutical Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “BioMarin Pharmaceutical (BMRN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biomarin-pharmaceutical-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.